A urokinase-activated recombinant anthrax toxin is selectively cytotoxic to many human tumor cell types

Molecular Cancer Therapeutics

Volumn 5, Issue 10, 2006, Pages 2556-2562

  Abi Habib, Ralph J ^a   Singh, Ravibhushan ^a   Liu, Shihui ^b   Bugge, Thomas H ^c   Leppla, Stephen H ^b   Frankel, Arthur E ^a  

^a SCOTT AND WHITE MEMORIAL HOSPITAL   (United States)

^b NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^c NATIONAL INSTITUTE OF DENTAL AND CRANIOFACIAL RESEARCH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTHRAX TOXIN; FURIN; MOLECULAR MARKER; PLASMINOGEN ACTIVATOR INHIBITOR 1; PROTEINASE; PROUROKINASE; UROKINASE; UROKINASE RECEPTOR;

ARTICLE; BREAST CANCER; CANCER CELL CULTURE; CELL TYPE; CONTROLLED STUDY; CYTOTOXICITY; DRUG POTENCY; DRUG SELECTIVITY; DRUG SENSITIVITY; DRUG TARGETING; ENZYME ACTIVATION; GROWTH INHIBITION; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; LUNG NON SMALL CELL CANCER; METASTASIS POTENTIAL; PANCREAS CANCER; PREDICTION; PRIORITY JOURNAL; PROTEIN EXPRESSION; TISSUE SPECIFICITY; TUMOR CELL; TUMOR GROWTH; TUMOR REGRESSION;

ANTIGENS, BACTERIAL; ANTINEOPLASTIC AGENTS; BACTERIAL TOXINS; CELL LINE, TUMOR; FURIN; HUMANS; PLASMINOGEN ACTIVATOR INHIBITOR 1; RECEPTORS, CELL SURFACE; RECEPTORS, PEPTIDE; RECOMBINANT PROTEINS; URINARY PLASMINOGEN ACTIVATOR;

EID: 33750454040     PISSN: 15357163     EISSN: None     Source Type: Journal    
DOI: 10.1158/1535-7163.MCT-06-0315     Document Type: Article

References (27)

1. Johansson N, Ahonen M, Kahari VM. Matrix metalloproteinases in tumor invasion. Cell Mol Life Sci 2000;57:5-15.
2. Andreasen PA, Egelund R, Petersen HH. The plasminogen activation system in tumor growth, invasion, and metastasis. Cell Mol Life Sci 2000; 57:25-40.
3. Dano K, Romer J, Nielsen BS, et al. Cancer invasion and tissue remodeling-cooperation of protease systems and cell types. APMIS 1999; 107:120-7.
4. Ploug M, Ostergaard S, Hansen LB, Holm A, Dano K. Photoaffinity labeling of the human receptor for urokinase-type plasminogen activator using a decapeptide antagonist. Evidence for a composite ligand binding site and a short interdomain separation. Biochemistry 1998;37:3612-22.
5. Garsdvall H, Dano K, Ploug M. Mapping part of the functional epitope for ligand binding on the receptor for urokinase type plasminogen activator by site directed mutagenesis. J Biol Chem 1999;274:37995-8003.
6. Duesbery NS, Webb CP, Leppla SH, et al. Proteolytic inactivation of MAP kinase kinase by anthrax lethal factor. Science 1998;280:734-7.
7. Bradley KA, Mogridge J, Mourez M, Collier RJ, Young JA. Identification of the cellular receptor for anthrax toxin. Nature 2001;414:225-9.
8. Wei W, Lu O, Chaudry GJ, Leppla SH, Cohen SN. The LDL receptor related protein LRP6 mediates internalization and lethality of anthrax toxin. Cell 2006;124:1141-54.
9. Abi Habib RJ, Urieto JO, Liu S, Leppla SH, Duesbery NS, Frankel AE. BRAF status and mitogen-activated protein/extracellular signal-regulated kinase kinase 1/2 activity indicate sensitivity of melanoma cells to anthrax lethal toxin. Mol Cancer Ther 2005;4:1303-10.
10. Solit DB, Garraway LA, Pratilas CA, et al. BRAF mutation predicts sensitivity to MEK inhibition. Nature 2006;439:358-62.
11. Liu S, Bugge TH, Leppla SH. Targeting of tumor cells by cell surface urokinase plasminogen activator-dependent anthrax toxin. J Biol Chem 2001;276:17976-84.
12. Liu S, Redeye V, Kuremsky JG, et al. Intermolecular complementation achieves high-specificity tumor targeting by anthrax toxin. Nat Biotechnol 2005;23:725-30.
13. Liu S, Aaronson H, Mitola DJ, Leppla SH, Bugge TH. Potent antitumor activity of a urokinase-activated engineered anthrax toxin. Proc Natl Acad Sci U S A 2003;100:657-62.
14. Rono B, Romer J, Liu S, Bugge TH, Leppla SH, Kristjansen PE. Antitumor efficacy of a urokinase activation-dependent anthrax toxin. Mol Cancer Ther 2006;5:89-96.
15. Abi-Habib RJ, Liu S, Bugge TH, Leppla SH, Frankel AE. A urokinase activated recombinant diphtheria toxin targeting the granulocyte-macrophage colony-stimulating factor receptor is selectively cytotoxic to human acute myeloid leukemia blasts. Blood 2004;104:2143-8.
16. Dano K, Behrendt N, Hoyer-Hansen G, et al. Plasminogen activation and cancer. Thromb Haemost 2005;93:631-40.
17. Meijer-van Gelder ME, Look MP, Peters HA, et al. Urokinase-type plasminogen activator system in breast cancer: association with tamoxifen therapy in recurrent disease. Cancer Res 2004;64:563-8.
18. Schmitt M, Harbeck N, Thomssen C, et al. Clinical impact of the plasminogen activation system in tumor invasion and metastasis: prognostic relevance and target for therapy. Thromb Haemost 1997;78: 285-96.
19. Setyono-Han B, Sturzebecher J, Schmalix WA, et al. Suppression of rat breast cancer metastasis and reduction of primary tumour growth by the small synthetic urokinase inhibitor WX-UK1. Thromb Haemost 2005; 93:779-86.
20. Rockway TW, Nienaber V, Giranda VL. Inhibitors of the protease domain of urokinase-type plasminogen activator. Curr Pharm Des 2002;8: 2541-58.
21. Cavallaro U, del Vecchio A, Lappi DA, et al. A conjugate between human urokinase and saporin, a type-1 ribosome-inactivating protein, is selectively cytotoxic to urokinase receptor-expressing cells. J Biol Chem 1993;268:23186-90.
22. Rajagopal V, Kreitman RJ. Recombinant toxins that bind to the urokinase receptor are cytotoxic without requiring binding to the α(2)-macroglobulin receptor. J Biol Chem 2000;275:7566-73.
23. Ramage JG, Vallera DA, Black JH, et al. The diphtheria toxin/urokinase fusion protein (DTAT) is selectively toxic to CD87 expressing leukemic cells. Leuk Res 2003;27:79-84.
24. Druker BJ, Tamura S, Buchdunger E, et al. Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells. Nat Med 1996;2:561-6.
25. Deininger MW, Goldman JM, Lydon N, Melo JV. The tyrosine kinase inhibitor CGP57148B selectively inhibits the growth of BCR-ABL-positive cells. Blood 1997;90:3691-8.
26. Baselga J, Norton L, Albanell J, Kim YM, Mendelsohn J. Recombinant humanized anti-HER2 antibody (Herceptin) enhances the antitumor activity of paclitaxel and doxorubicin against HER2/neu overexpressing human breast cancer xenografts. Cancer Res 1998;58:2825-31.
27. Pegram MD, Lipton A, Hayes DF, et al. Phase II study of receptor-enhanced hemosensitivity using recombinant humanized anti-p185HER2/neu monoclonal antibody plus cisplatin in patients with HER2/neu-overexpressing metastatic breast cancer refractory to chemotherapy treatment. J Clin Oncol 1998;16:2659-71.